News

Stock freefalls after obesity miss

Posted 21 August 2025 PM

Viking Therapeutics, which up until now has posed a threat in the hot oral obesity drug space, has hit a hurdle with disappointing data from a Phase 2 trial sending its share price into a freefall.

The company's stock plummeted almost 40 per cent after news its oral obesity drug candidate resulted in weight loss of up to 12.2 per cent after 13 weeks - but the real sticking point, 38 per cent of participants discontinued treatment at the most effective dose.

To see the whole article, please login